Slow-onset adaptive changes that arise from sustained antidepressant treatment, such as enhanced adult hippocampal neurogenesis and increased trophic factor expression, play a key role in the behavioral effects of antidepressants. ␣ 2 -Adrenoceptors contribute to the modulation of mood and are potential targets for the development of faster acting antidepressants. We investigated the influence of ␣ 2 -adrenoceptors on adult hippocampal neurogenesis. Our results indicate that ␣ 2 -adrenoceptor agonists, clonidine and guanabenz, decrease adult hippocampal neurogenesis through a selective effect on the proliferation, but not the survival or differentiation, of progenitors. These effects persist in dopamine ␤-hydroxylase knock-out (Dbh Ϫ/Ϫ ) mice lacking norepinephrine, supporting a role for ␣ 2 -heteroceptors on progenitor cells, rather than ␣ 2 -autoreceptors on noradrenergic neurons that inhibit norepinephrine release. Adult hippocampal progenitors in vitro express all the ␣ 2 -adrenoceptor subtypes, and decreased neurosphere frequency and BrdU incorporation indicate direct effects of ␣ 2 -adrenoceptor stimulation on progenitors. Furthermore, coadministration of the ␣ 2 -adrenoceptor antagonist yohimbine with the antidepressant imipramine significantly accelerates effects on hippocampal progenitor proliferation, the morphological maturation of newborn neurons, and the increase in expression of brain derived neurotrophic factor and vascular endothelial growth factor implicated in the neurogenic and behavioral effects of antidepressants. Finally, short-duration (7 d) yohimbine and imipramine treatment results in robust behavioral responses in the novelty suppressed feeding test, which normally requires 3 weeks of treatment with classical antidepressants. Our results demonstrate that ␣ 2 -adrenoceptors, expressed by progenitor cells, decrease adult hippocampal neurogenesis, while their blockade speeds up antidepressant action, highlighting their importance as targets for faster acting antidepressants.
Introduction
Depression is a prevalent psychiatric disorder, and current antidepressant medications share the major drawback of a delayed onset of therapeutic action (Thompson, 2002) . While the mechanisms underlying this time lag are poorly understood, slowonset adaptive changes in corticolimbic brain regions like the hippocampus are hypothesized to contribute to the delayed beneficial effects of antidepressants (Sahay and Hen, 2007; Krishnan and Nestler, 2008) . Hippocampal plasticity induced in response to chronic antidepressant treatment occurs both at the cellular level, through an increase in adult hippocampal neurogenesis (Malberg et al., 2000) , and at the molecular level, via increased expression of trophic factors like brain derived neurotrophic factor (BDNF) (Nibuya et al., 1995) and vascular endothelial growth factor (VEGF) (Warner-Schmidt and Duman, 2007) . The neurogenic changes following chronic antidepressant treatment involve both increased progenitor proliferation and morphological maturation of newborn neurons (Wang et al., 2008) . These molecular and cellular adaptations arise only after 2-3 weeks of sustained antidepressant administration, and are demonstrated to play an important role in the behavioral effects of antidepressants (Shirayama et al., 2002; Santarelli et al., 2003; Airan et al., 2007; Warner-Schmidt and Duman, 2007) . Treatments that would hasten the onset of these adaptive changes are of particular interest, as they may serve to identify putative rapid action antidepressants.
A slow recovery is not an inherent feature of depression, as electroconvulsive seizure therapy and combination drug treatments are reported to exhibit faster clinical effects (Daly et al., 2001; Blier, 2003) . Among the targets for adjunct drug therapy is the ␣ 2 -adrenoceptor (Blier, 2003) . Clinical evidence indicates that coadministration of the ␣ 2 -adrenoceptor antagonist yohimbine with an antidepressant hastens improvement in mood, and antidepressants that exhibit preferential ␣ 2 -adrenoceptor antagonism like mirtazapine can exhibit faster therapeutic effects (Quitkin et al., 2001; Carpenter et al., 2002; Sanacora et al., 2004) . Furthermore, chronic antidepressant treatments have been demonstrated to desensitize and/or downregulate the ␣ 2 -adrenoceptor, an effect speculated to play an important role in determining the speed of antidepressant action (Esteban et al., 1999; Andrade and Sudha, 2000) . Several studies indicate enhanced ␣ 2 -adrenoceptor mRNA, binding density or function in animal models of depression, and in postmortem studies of major depression (Fulford et al., 1994; Callado et al., 1998; García-Vallejo et al., 1998; García-Sevilla et al., 1999; Ribas et al., 2001) . While preclinical and clinical studies implicate ␣ 2 -adrenoceptors in both the pathogenesis and treatment of depression, thus far little is known about how ␣ 2 -adrenoceptors regulate key adaptive plastic processes such as adult hippocampal neurogenesis that are thought to play an important role in antidepressant efficacy.
The present study was performed to assess the influence of ␣ 2 -adrenoceptors on adult hippocampal neurogenesis using in vivo and in vitro approaches. Furthermore, we addressed whether adjunct ␣ 2 -adrenoceptor antagonist treatment with an antidepressant accelerates the onset of adaptive changes such as increased hippocampal neurogenesis and enhanced trophic factor expression, and whether this translates into faster behavioral effects of antidepressant treatment in animal models. Our results underscore the importance of the ␣ 2 -adrenoceptor as a target for the development of faster acting antidepressants.
Materials and Methods
Animals. Adult male Wistar rats (250 -300 g, 2 months of age) bred in the Tata Institute of Fundamental Research (TIFR) animal colony were used in the present study. Animals were group housed and maintained on a 12 h light/dark cycle with access to food and water ad libitum. For dispersed hippocampal progenitor culture studies, adult Wistar rats were used, and for the neurosphere assays, Wistar rat pups (7 d) were used. For the Dopamine ␤-hydroxylase (Dbh) knock-out experiments, adult Dbh ϩ/Ϫ and Dbh Ϫ/Ϫ mice, maintained on a mixed 129/SvEv and C57BL/6J background and generated as previously described (Thomas et al., 1995; Thomas and Palmiter, 1998) were used. Pregnant Dbh ϩ/Ϫ mice were given the adrenergic receptor agonists, isoproterenol and phenylephrine (20 g/ml each) ϩ vitamin C (2 mg/ml) from embryonic day 9.5 (E9.5)-E14.5, and L-3,4-dihydroxyphenylserine (DOPS; 2 mg/ml ϩ vitamin C 2 mg/ml) from E14.5-birth in their drinking water to rescue the embryonic lethality associated with the Dbh Ϫ/Ϫ mutation. Dbh ϩ/Ϫ mice were used as controls because they have normal norepinephrine/epinephrine levels and are phenotypically indistinguishable from Dbh ϩ/ϩ mice (Thomas et al., 1995; Thomas and Palmiter, 1998; Szot et al., 1999) . Since no sex differences in hippocampal neurogenesis were observed, female Dbh ϩ/Ϫ and Dbh Ϫ/Ϫ mice were used in this study. For the ␣ 2A -and ␣ 2C -adrenoceptor knock-out studies, adult male mutant mice generated as previously described Hein et al., 1999) were used. The ␣ 2AC knock-out mice were generated through crossing the single-knock-out strains . For all mouse studies, animals 3-6 months of age were used and genotypes were confirmed using PCR. All animal procedures were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the TIFR Institutional Animal Ethics committee, Animal Ethics Committee of the University of Queensland, the Emory University Animal Care and Use Committee, or the University of Freiburg, and appropriate government authorities.
Drug treatments and BrdU labeling paradigms. To study the influence of ␣ 2 -adrenoceptor stimulation, the ␣ 2 -adrenoceptor agonists, clonidine (1 mg/kg; Sigma), or guanabenz (2 mg/kg; Sigma) were used. To address the effects of ␣ 2 -adrenoceptor blockade, the ␣ 2 -adrenoceptor antagonists, yohimbine (2 mg/kg; Sigma) or RX811059 (2-ethoxy-idazoxan, 2.5 mg/kg; Sigma) were used. For the antidepressant studies, animals received treatment with the tricyclic antidepressant imipramine (20 mg/kg, Sigma). The vehicle used in this study was 0.9% saline, with the exception of yohimbine, for which it was 10% DMSO. The choice of drug doses was based on previous studies (Dursun and Handley, 1993; García-Vallejo et al., 1998; Bortolozzi and Artigas, 2003; Gobert et al., 2003; Sairanen et al., 2005; Nair et al., 2006) and all drugs were administered via intraperitoneal injection.
To study the influence of ␣ 2 -adrenoceptor stimulation or blockade on the proliferation of adult hippocampal progenitors, animals received two different treatment regimes (acute and chronic). In the acute treatment regime, rats received a single injection of the ␣ 2 -adrenoceptor drugs (clonidine, guanabenz, yohimbine, or RX811059) or vehicle, followed 45 min later by a single injection of the mitotic marker 5-bromo-2Ј-deoxyuridine (BrdU, 200 mg/kg; Sigma) and were killed 2 h later (n ϭ 6/group; each experiment had its individual vehicle group). In the chronic treatment regime, rats received treatment with the ␣ 2 -adrenoceptor drugs (clonidine, guanabenz, or yohimbine) or vehicle once daily for 7 d. On the last day of treatment, 2 h after drug or vehicle administration, animals received a single injection of BrdU (200 mg/kg) and were killed 24 h later (n ϭ 5-6/group; each experiment had its individual vehicle group). To address whether the effects of ␣ 2 -adrenoceptor stimulation on hippocampal progenitor proliferation could be prevented by prior ␣ 2 -adrenoceptor blockade, animals were divided into four experimental groups (vehicle/vehicle, vehicle/ clonidine, yohimbine/vehicle and yohimbine/clonidine, n ϭ 10/group; yohimbine/vehicle group, n ϭ 6). The two injections were separated by 30 min. BrdU was administered 45 min after the last injection and the animals were killed 2 h later.
Dbh mutant mice were used to address whether the effects of ␣ 2 -adrenoceptor agonists on adult hippocampal progenitor proliferation involve stimulation of inhibitory ␣ 2 -autoreceptors or ␣ 2 -heteroceptors on target neurons. Because Dbh Ϫ/Ϫ mice lack endogenous norepinephrine, any effect of ␣ 2 -adrenoceptor agonists in these mice must be mediated by ␣ 2 -heteroceptors. Dbh ϩ/Ϫ and Dbh Ϫ/Ϫ mice received treatment with guanabenz (2 mg/kg) or vehicle once daily for 7 d. On the last day of treatment, 2 h after drug or vehicle administration, animals received a single injection of BrdU (200 mg/kg) and were killed 24 h later (n ϭ 5-6/group). To address the role of individual ␣ 2 -adrenoceptor subtypes on adult hippocampal progenitor proliferation, ␣2A, ␣2C and ␣2AC knock-out and wild-type control mice received a single administration of BrdU (100 mg/kg) and were killed 2 h later (n ϭ 4 -5/group).
To determine the influence of ␣ 2 -adrenoceptor stimulation or blockade on the survival and differentiation of adult hippocampal progenitors, drug-naive rats first received BrdU (200 mg/kg) once daily for three consecutive days. Five days following the last BrdU treatment, a time point at which BrdU-positive cells are likely to be postmitotic (Cameron and McKay, 2001) , rats received treatment with the ␣ 2 -adrenoceptor agonist clonidine, the ␣ 2 -adrenoceptor antagonist yohimbine and respective vehicle treatment once daily for 21 d and were killed 24 h after the final drug treatment (n ϭ 4 -6/group). To assess effects of ␣ 2 -adrenoceptor stimulation on hippocampal progenitor maturation at earlier time-points after BrdU labeling, drug-naive animals first received BrdU (100 mg/kg) twice daily for two consecutive days followed by a single BrdU injection on the third day. Treatment with the ␣ 2 -adrenoceptor agonist, guanabenz, commenced the day after the final BrdU injection and continued for seven consecutive days. Animals were killed 24 h after the final vehicle/guanabenz treatment (n ϭ 4/group).
To address the influence of ␣ 2 -adrenoceptor blockade on the behavioral and neurogenic effects of the antidepressant imipramine, rats were divided into four treatment groups: vehicle/vehicle, yohimbine/vehicle, vehicle/imipramine, yohimbine/imipramine (n ϭ 10/group). The two injections were spaced apart by 30 min. All four groups received the above described drug treatment regime for 7 or 21 d. Two hours after the last drug treatment animals were tested for their behavior in the novelty suppressed feeding (NSF) test. The NSF test is reported to be responsive to chronic administration of classical antidepressants for 2-3 weeks (Bodnoff et al., 1988; Santarelli et al., 2003) . Following the NSF test, animals were injected with BrdU (200 mg/kg, i.p.) and were killed 24 h later to address effects on progenitor proliferation using BrdU immunohistochemistry and immature neuron numbers using DCX immunohistochemistry. Furthermore, a group of animals that received the above treatment regime for 14 d was also used to address effects on endogenous markers of hippocampal neurogenesis (n ϭ 6/group). An additional group of animals (n ϭ 6/group) from the 7 d drug treatment regime were killed 28 d after the final BrdU treatment to study differentiation of BrdU-labeled hippocampal progenitors into neurons or glia. To address whether the 7 d combined drug treatment regime influences hippocampal progenitor maturation, drug-naive animals first received BrdU (100 mg/kg) twice daily for two consecutive days followed by a single BrdU injection on the third day. Animals were divided into the four treatment groups as described above, received the 7 d drug treatment paradigm with yohimbine and imipramine, and were killed 24 h after the final treatment (n ϭ 5/group).
To address the effects of a short-duration (7 d) combined treatment with yohimbine and imipramine on gene expression in the hippocampus, animals received vehicle or yohimbine injections followed 30 min later by vehicle or imipramine treatment as described above, and were killed 2 h after the last injection (n ϭ 4/group). To assess the influence of a short-duration (7 d) treatment with yohimbine and imipramine on norepinephrine levels in the hippocampus, animals received vehicle or yohimbine injections followed 30 min later by vehicle or imipramine treatment as described above (n ϭ 6/group).
Dispersed adult hippocampal progenitor cultures. Dissociated adult hippocampal progenitor cell cultures were generated from adult male Wistar rats (2 months) based on a previously described method (Palmer et al., 1999) , and cells were cultured in DMEM/F-12 with N2 supplement (Invitrogen) and 40 ng/ml FGF-2 (R&D Systems) on poly-ornithine-(Sigma) and laminin-(Sigma) coated tissue culture plates. Hippocampal progenitors were plated in 16-well poly-ornithine-and laminin-coated Labtek chamber slides (Nunc) at a density of 5 ϫ 10 5 cells/well. To address the influence of ␣ 2 -adrenoceptor stimulation or blockade on hippocampal progenitor proliferation, cells were exposed for 24 h to growth medium with or without clonidine (10, 50, and 100 M) or yohimbine (10, 50, and 100 M). Cells were then exposed to a pulse of BrdU (40 M, Sigma) for 2 h and were fixed by exposure to 4% paraformaldehyde (PFA) for 15 min before further processing. In vitro drug doses were selected based on prior literature (Ortego and Coca-Prados, 1998; Han et al., 2007) . To examine the expression of ␣ 2A -, ␣ 2B -, and ␣ 2C -adrenoceptor subtypes in hippocampal progenitors, total RNA was isolated from the dispersed hippocampal progenitor cultures (Oligotex Direct RNA kit, Qiagen) and PCR was performed on reverse transcribed cDNA using specific forward and reverse primers. The primer sequences (DNA Technology) for ␣ 2A -, ␣ 2B -, and ␣ 2C -adrenoceptors and ␤-actin were based on prior literature (Faber et al., 2001; Mori et al., 2002) .
Neurosphere assay. Seven-day-old Wistar pups were killed under isoflurane-induced anesthesia and hippocampi were dissected out into HEPES-buffered Eagle's medium. Hippocampal tissue was minced, treated with 0.1% trypsin-EDTA for 5 min at 37°C, and digestion was stopped by adding trypsin inhibitor (0.014% w/v, Sigma). Tissue was triturated to obtain a single cell suspension, and cells were plated at 1000 cells/well in a 96-well plate and cultured in NeuroCult NSC basal medium with proliferation supplements (StemCell Technologies), 2% bovine serum albumin (Invitrogen), 2 g/ml heparin (Sigma), epidermal growth factor (20 ng/ml, BD Biosciences), and basic fibroblast growth factor (10 ng/ml, Roche). Cells were treated with clonidine (100 M), guanabenz (10 M), or yohimbine (10 M) for the duration of the experiment. In vitro drug doses were selected based on prior literature (Ortego and Coca-Prados, 1998; Dunbar et al., 2006; Han et al., 2007) . In each experiment, 20 wells were plated per treatment group and the experiment was repeated three times. The number of neurospheres (Ͼ100 m) obtained per well was counted after 10 d in culture.
Immunohistochemistry and immunofluorescence. Animals were killed through transcardial perfusion with 4% PFA, and serial coronal sections (50 m) through the rostrocaudal extent of the hippocampus were generated on a vibratome. Sections were processed for BrdU, proliferating cell nuclear antigen (PCNA) or doublecortin (DCX) immunohistochemistry as described previously (Kulkarni et al., 2002 , Jha et al., 2006 . In brief, BrdU immunohistochemistry involved DNA denaturation and acid hydrolysis followed by overnight incubation with anti-BrdU antibody (mouse anti-BrdU, 1:500, Boehringer Mannheim; rat anti-BrdU, 1:500, Accurate Biochemicals) before treatment with secondary antibody (biotinylated anti-mouse IgG or anti-rat IgG, 1:500, Vector Laboratories or Cy3-conjugated anti-mouse IgG, 1:1000, Invitrogen). For PCNA immunohistochemistry, sections were subjected to antigen retrieval in 0.1 M PB at 80°C for half an hour before blocking and overnight incubation with mouse anti-PCNA (1:250, Millipore Bioscience Research Reagents) followed by incubation with biotinylated horse anti-mouse secondary antibody (1:250, Vector) for 2 h. For DCX immunohistochemistry, sections were incubated with goat anti-DCX antibody (1:250, Santa Cruz Biotechnology) overnight followed by incubation with a biotinylated rabbit anti-goat secondary antibody (1:500, Vector) for 2 h. For NeuroD immunohistochemistry, sections were incubated with goat anti-NeuroD antibody (1:250, Santa Cruz Biotechnology) overnight followed by incubation with a biotinylated rabbit anti-goat secondary antibody (1:500, Vector) for 2 h. Signal amplification was performed using a Vectastain Elite Avidin-Biotin system (Vector) and was visualized using diaminobenzidine (Sigma) as a substrate.
For double label immunofluorescence, sections subjected to DNA denaturation and acid hydrolysis were exposed to the following combinations of antibodies: (1) mouse anti-BrdU (1:500, Roche) and goat anticalretinin (1:250; Millipore Bioscience Research Reagents), (2) mouse anti-BrdU (1:500, Roche) and goat anti-DCX (1:250; Santa Cruz Biotechnology) overnight at room temperature. Sections were incubated with a mixture of secondary antibodies: biotinylated anti-mouse IgG (1:250, Vector) and rhodamine-conjugated anti-goat IgG (1:250, Invitrogen) before incubation with fluorescein-conjugated streptavidin (1: 500, GE Healthcare) for 1 h.
For triple label immunofluorescence, sections subjected to DNA denaturation and acid hydrolysis were exposed to a mixture of antibodies: rat anti-BrdU (1:200, Accurate Biochemicals), mouse anti-neuronal nuclei (NeuN; 1:1000; Millipore Bioscience Research Reagents) and rabbit anti-glial fibrillary acidic protein (GFAP; 1:500; Sigma) overnight at room temperature. Sections were incubated with a mixture of secondary antibodies: biotinylated anti-rat IgG (1:500, Millipore Bioscience Research Reagents), rhodamine-conjugated anti-mouse IgG (1:500, Millipore Bioscience Research Reagents), and Cy-5-conjugated anti-rabbit IgG (1:500, Millipore Bioscience Research Reagents) for 2 h, followed by incubation with fluorescein-conjugated streptavidin (1:500, GE Healthcare) for 1 h.
Cell counting analysis. All cell counting analysis was performed on coded sections by an experimenter blind to the study code. Quantitation of BrdU-positive cell numbers in tissue sections was carried out using a previously described modified, unbiased stereology protocol (Malberg et al., 2000) on a Zeiss Axioskop microscope. Sections spanned the rostrocaudal extent of the hippocampus and every fifth hippocampal section was processed for BrdU quantitation (10 sections/animal). BrdU-positive cells within dentate gyrus (DG) were counted as being in the subgranular zone (SGZ)/granule cell layer (GCL) when they were directly touching the SGZ or within it. The total number of BrdU-positive cells per SGZ/GCL was estimated by multiplying the total number of BrdU-positive cells counted by the section periodicity (5) and results are expressed as the total number of BrdU-positive cells per SGZ/GCL. Quantitation of PCNA-positive cells followed the same approach described above for BrdUquantitation. To determine DCX-or NeuroD-positive cell number in the hippocampus, the number of DCX-or NeuroD-positive cells in the DG were quantitated (four to six sections/animal) and results were expressed as the number of DCX-or NeuroD-positive cells per section. Furthermore, we also examined the morphological status of DCX-positive cells by categorizing them as (1) DCX-positive cells without tertiary dendrites or (2) DCX-positive cells with complex tertiary arbors (Wang et al., 2008) . Quantitation of both DCXpositive cell number and morphological category was performed using a Zeiss Axioskop at a magnification of 400ϫ.
To address effects on the maturation of hippocampal progenitors, the percentage of BrdU-positive cells that colocalized with the markers calretinin or DCX was determined using confocal microscopy. A minimum of 60 (BrdU/calretinin) or 30 (BrdU/DCX) BrdU-positive cells from each animal (4 sections, 500 m apart) were analyzed using z-plane confocal sectioning with 1 m steps on a Biorad MRC1024 to confirm colocalization of BrdU with calretinin or DCX. To study progenitor differentiation into NeuN-positive neurons or GFAP-positive glia, the percentage of BrdU-positive cells that colocalized with NeuN or GFAP was assessed. A minimum of 30 BrdU-positive cells from each animal (8 sections, 250 m apart) was analyzed using z-plane sectioning with 0.5 m steps on a Biorad MRC1024 confocal microscope to confirm colocalization with either NeuN or GFAP.
Quantitation of the numbers of BrdU-positive cells in adult rat hippocampal progenitor cultures was done using an epifluorescent Zeiss microscope by an experimenter blind to the treatment conditions. The percentage of DAPI-positive cells per field that were labeled with BrdU was determined. The number of BrdU-positive cells for the proliferation experiment was counted in Ͼ600 cells/well (three random, nonoverlapping individual fields per well) and three wells were scored per treatment condition.
In situ hybridization and autoradiogram quantitation. In situ hybridization was carried out as previously described (Nair et al., 2007) . In brief, 14 m cryostat cut coronal sections were fixed, acetylated and dehydrated before storage at Ϫ70°C. Rat BDNF, VEGF, fibroblast growth factor-2 (FGF-2), VGF (not an acronym), activity regulated cytoskeletal protein (Arc), and cAMP response element binding protein (CREB) cRNA probes were generated from either transcription competent plasmids or PCR generated templates. Plasmids for BDNF, FGF-2, VGF, Arc, and CREB were kindly provided by Dr. Julie Lauterborn (University of California, Irvine, Irvine, CA), Dr. Sondra Bland (University of Colorado at Boulder, Boulder, CO), Dr. Shubha Tole (Tata Institute of Fundamental Research, Mumbai, India), Dr. Oswald Steward (John Hopkins University, Baltimore, MD), and Dr. Ronald Duman (Yale University, New Haven, CT) respectively. The VEGF template for VEGF exon 3 was PCR generated using a forward primer with a T3 site and a reverse primer with a T7 site (forward primer: AATTAACCCTCACTAAAGGGTCCAATT-GAGACCCTGGTG; reverse primer: TAATACGACTCACTATAGGGC-CATAGTGACGTTGCTCTCCG). cRNA probes were transcribed using 35 S-labeled UTP (GE Healthcare), and slides were incubated with 35 S-UTP labeled riboprobes at a concentration of 2 ϫ 10 6 cpm/150 l in hybridization buffer. After hybridization, slides were subjected to RNase A (20 g/ml) treatment at 45°C for 30 min, followed by stringent washes in decreasing concentrations of SSC. Slides were air dried and exposed to Hyperfilm ␤-max (GE Healthcare) for 1-2 weeks. Autoradiograms were analyzed using the Macintosh-based Scion Image software (Scion). To correct for nonlinearity, 14 C standards were used for calibration. The dentate gyrus granule cell region was analyzed and an equivalent area was outlined for each sample. Optical density measurements from both sides of 3-4 individual sections from each animal were analyzed, from which the mean value was calculated. Sense riboprobes or a ribonuclease A pretreatment wash (40 g/ml at 37°C for 30 min) did not yield any significant hybridization (data not shown) confirming the specificity of signal.
Novelty suppressed feeding test. To address the influence of ␣ 2 -adrenoceptor blockade on the behavioral effects of the antidepressant imipramine, animals were subjected to the NSF paradigm, which has been previously reported to demonstrate differences in behavior following chronic, but not acute, antidepressant treatment (Bodnoff et al., 1988; Santarelli et al., 2003) . Rats in the four different treatment groups, vehicle/vehicle, yohimbine/vehicle, vehicle/imipramine, and yohimbine/ imipramine were tested on day 7 and day 21 of treatment in two distinct experiments. Food was withdrawn 48 h before the test with water available ad libitum. The test was performed in a black rectangular box of dimensions (52 ϫ 48 ϫ 32 cm) kept in a dark room. Food pellets were placed in the center of the box on a small elevated platform that was brightly illuminated. At the start of the test, rats were placed in a dark corner of the box facing the wall and were observed for a period lasting 5 min. The latency to feed was determined and animals that did not approach the food pellet were given a score of 300 s equaling the entire duration of the test. At the end of the test, animals were transferred to their home cages with food available, and their food consumption was measured for 30 min.
Biochemical detection of norepinephrine. To assess the levels of norepinephrine in the hippocampus following combined treatment with yohimbine and imipramine for 7 d, high performance liquid chromatography (HPLC) was used. Twenty-four hours after the final treatment, hippocampi were rapidly dissected out and frozen in liquid nitrogen. Homogenates were generated through sonication of hippocampi in 0.1 M perchloric acid followed by centrifugation at 15,000 rpm for 10 min at 4°C. Supernatants were processed for determination of norepinephrine. Levels of norepinephrine were determined with a fluorometric detection method for HPLC analysis as described previously (Lakshmana and Raju, 1997) using purified norepinephrine (Sigma) as a standard.
Statistical analysis. Results were subjected to statistical analysis using the statistical software Prism (Graphpad). Experiments with two groups were analyzed for differences using the unpaired Student's t test, with significance determined at p Ͻ 0.05. Experiments with three groups or more were subjected to statistical analyses using one-way or two-way ANOVA with significance determined at p values Ͻ0.05, followed by the Bonferroni post hoc test for group comparisons. The two-way ANOVA was used to assess interaction effects between two factors, namely: (1) ␣ 2 -adrenoceptor antagonist, yohimbine and ␣ 2 -adrenoceptor agonist, clonidine, (2) genotype (Dbh) and ␣ 2 -adrenoceptor agonist, guanabenz, and (3) the antidepressant, imipramine and the ␣ 2 -adrenoceptor antagonist, yohimbine.
Results
␣ 2 -Adrenoceptor stimulation decreases adult hippocampal progenitor proliferation in vivo Acute (single injection) (Fig. 1) or chronic (once daily injections for 7 d) (supplemental Fig. 1 , available at www.jneurosci.org as supplemental material) treatments with the ␣ 2 -adrenoceptor agonists, guanabenz or clonidine, resulted in a significant decline in the proliferation of adult hippocampal progenitors, assessed using the mitotic marker BrdU. BrdU-positive cells were predominantly localized to the SGZ (Fig. 1 B) lining the border of the GCL and the hilus. Analysis of the numbers of BrdU-positive cells in the SGZ, using unbiased stereological approaches, revealed a significant decline of 34% and 38% in BrdU-positive cell number after acute guanabenz (Fig. 1C ) or acute clonidine (Fig. 1C) treatment respectively. Chronic treatments with guanabenz or clonidine (supplemental Fig. 1 , available at www.jneurosci.org as supplemental material) resulted in a 45% and 32% decline in the numbers of BrdU-positive cells in the SGZ respectively. To corroborate the effects of ␣ 2 -adrenoceptor stimulation on adult hippocampal progenitor proliferation observed with BrdU, we also examined the effect of acute clonidine treatment on an endogenous marker of cell division, PCNA. Acute clonidine treatment resulted in a significant decline (35%) in the number of PCNApositive cells within the SGZ (supplemental Fig. 1 , available at www.jneurosci.org as supplemental material).
Next, we addressed whether pretreatment with the ␣ 2 -adrenoceptor antagonist, yohimbine, would block the effects of clonidine on hippocampal progenitor proliferation. Pretreatment with yohimbine completely blocked the clonidine-induced decline in BrdU-positive cell number observed within the SGZ (supplemental Fig. 1 , available at www.jneurosci.org as supplemental material). Two-way ANOVA revealed a significant yohimbine ϫ clonidine interaction (F (1,26) ϭ 11.59, p ϭ 0.0022). Furthermore, to assess whether ␣ 2 -adrenoceptor blockade itself influences adult hippocampal progenitor proliferation, animals received acute treatments with the ␣ 2 -adrenoceptor antagonists, yohimbine or RX811059. Acute treatment with either of the ␣ 2 -adrenoceptor antagonists did not alter the number of BrdUpositive cells within the SGZ ( ␣ 2 -Adrenoceptor stimulation induced decline in adult hippocampal progenitor proliferation persists in Dbh Ϫ/Ϫ mice ␣ 2 -Adrenoceptors are coupled to G i protein, inhibit adenylyl cyclase, and exist both as presynaptic inhibitory autoreceptors that control norepinephrine release and as ␣ 2 -heteroceptors on target neurons receiving noradrenergic input. Dbh Ϫ/Ϫ mice were used to distinguish whether the effects of ␣ 2 -adrenoceptor stimulation on progenitor proliferation are mediated by ␣ 2 -autoreceptors or heteroceptors. Because Dbh Ϫ/Ϫ mice lack norepinephrine, ␣ 2 -adrenoceptor agonists cannot produce effects via autoreceptor modulation of norepinephrine release; their only activity is via ␣ 2 -heteroceptors (Szot et al., 2004) . Chronic administration of the ␣ 2 -adrenoceptor agonist, guanabenz, to Dbh Ϫ/Ϫ mice resulted in a significant decline in the number of BrdU-positive cells in the SGZ (Fig. 2) . The extent of this significant decline in hippocampal progenitor proliferation was similar to that observed in Dbh ϩ/Ϫ controls treated with guanabenz. Twoway ANOVA indicated no genotype ϫ guanabenz interaction (F (1,13) ϭ 0.07, p ϭ 0.80). The persistence of the guanabenzinduced impairment of hippocampal progenitor proliferation in Dbh Ϫ/Ϫ mice supports a role for ␣ 2 -heteroceptors in vivo. However, it is not possible to rule out a role for other factors released by noradrenergic nerve terminals following ␣ 2 -autoreceptor stimulation that may modulate hippocampal progenitor turnover. Dbh Ϫ/Ϫ mice did not exhibit a baseline decrease in hippocampal progenitor proliferation as compared to Dbh ϩ/Ϫ controls (Fig. 2 B) . This suggests that genetic loss of norepinephrine through postnatal development and adulthood does not produce a significant alteration in the proliferation of adult hippocampal progenitors, unlike the decline observed with pharmacological norepinephrine depletion in adult animals (Kulkarni et al., 2002) , suggesting possible compensatory mechanisms (Weinshenker et al., 2002; Schank et al., 2006) . ␣ 2 -Adrenoceptor stimulation decreases proliferation of adult hippocampal progenitors in vitro Given that the effects of ␣ 2 -adrenoceptor agonists on hippocampal progenitor proliferation likely involve ␣ 2 -heteroceptors, we next sought to address whether adult hippocampal progenitors express ␣ 2 -adrenoceptor subtypes and whether ␣ 2 -adrenoceptor agonists modulate their proliferation in vitro. RT-PCR on nestin immunopositive, dispersed adult hippocampal progenitors in culture (Fig. 3 A, B) demonstrated the mRNA expression of ␣ 2A -, ␣ 2B -, and ␣ 2C -adrenoceptor subtypes (Fig. 3C) . To examine the effects of ␣ 2 -adrenoceptor stimulation on the proliferation of adult hippocampal progenitors in culture, progenitor cells were exposed to clonidine (10, 50, or 100 M) for 24 h before a BrdU pulse for 2 h to determine the number of progenitors entering the S-phase of cell cycle. ␣ 2 -Adrenoceptor stimulation with clonidine led to a significant decrease in the numbers of BrdU-positive cells labeled in vitro (Fig. 3D-F ) . Similar to the in vivo results obtained with ␣ 2 -adrenoceptor antagonists, hippocampal progenitors in vitro treated with yohimbine (10, 50, or 100 M) did not exhibit any change in proliferation (data not shown).
To further ascertain whether the ␣ 2 -adrenoceptor agonist induced decline in hippocampal progenitor proliferation is mediated through a direct effect on hippocampal progenitors, we also performed the neurosphere assay (Fig. 3G) . Exposure of neurosphere cultures to clonidine or guanabenz resulted in a significant reduction in neurosphere formation (Fig. 3H ). While treatment with guanabenz resulted in a robust and significant (44%) decline in neurosphere formation, the percentage decline induced by clonidine treatment, though significant, was relatively small (14%) (Fig.  3H) . In contrast, treatment with yohimbine did not alter the numbers of neurospheres generated (Fig. 3H) . Together, these results demonstrate that the direct stimulation of ␣ 2 -adrenoceptors on hippocampal progenitors inhibits proliferation.
Adult hippocampal progenitor proliferation is unaffected in ␣ 2A -, ␣ 2C -, and ␣ 2AC -adrenoceptor knock-out mice To address whether turnover of adult hippocampal progenitors is altered in ␣ 2 -adrenoceptor subtype knock-out mice, we examined the number of BrdUpositive cells in ␣ 2A Ϫ/Ϫ , ␣ 2C Ϫ/Ϫ , and ␣ 2AC Ϫ/Ϫ mice. Total numbers of BrdUpositive cells in the SGZ of ␣ 2A -, ␣ 2C -, and ␣ 2AC -adrenoceptor knock-out mice were not different from those of wild-type controls (Table 1) . Furthermore, we examined the numbers of cells expressing DCX, an endogenous marker of immature newborn neurons, and observed no difference in the numbers of DCX-positive cells in ␣ 2A -, ␣ 2C -, and ␣ 2AC -adrenoceptor knock-out mice compared with wild-type controls (Table 1) .
␣ 2 -Adrenoceptor stimulation or blockade does not influence the survival and differentiation of adult hippocampal progenitors To examine the influence of ␣ 2 -adrenoceptor agonist or antagonist treatment on the survival and differentiation of adult hippocampal progenitors, drug-naive animals first received BrdU injections (Fig. 4 A) . Administration of either clonidine or yohimbine commenced 5 d after BrdU treatment and continued for 21 d (Fig. 4 A) . This particular BrdU labeling paradigm allows us to assess whether the postmitotic survival, or differentiation, of a BrdU-labeled cohort of hippocampal progenitors is influenced by ␣ 2 -adrenoceptor stimulation or blockade.
The survival of hippocampal progenitors in the SGZ/GCL was unaffected by clonidine or yohimbine treatment, as the numbers of BrdU-positive cells that persist in the SGZ/GCL was unchanged in both the clonidine- (Fig. 4 B, C ) and yohimbine- (Fig.  4 B, D) treated groups compared with their respective vehicletreated controls. We then determined whether the differentiation of BrdU-positive progenitors in the SGZ/GCL into a neuronal (NeuN-immunopositive, Fig. 4G ) or glial (GFAP-immunopositive, Fig. 4 H) fate is influenced by ␣ 2 -adrenoceptor stimulation or blockade. Confocal analysis with z-plane sectioning indicated no change in the percentage of BrdU-positive cells that acquired a neuronal or glial phenotype in vehicle-versus clonidine- (Fig.  4 E) or yohimbine-treated groups (Fig. 4 F) . A majority of BrdU- Wild-type, ␣ 2A -, ␣ 2C -, and ␣ 2AC -adrenoceptor subtype knock-out mice were injected with the mitotic marker BrdU as described in Materials and Methods. Quantitative analysis of BrdU-positive cells in the SGZ/GCL indicated no difference in the proliferation of adult hippocampal progenitors in ␣ 2 -adrenoceptor subtype knock-out mice compared with wild-type controls. The results are expressed as mean Ϯ SEM BrdU-positive cells per SGZ/GCL (n ϭ 5-6/group). Furthermore, the number of DCX-immunopositive immature neurons was also unchanged in ␣ 2 -adrenoceptor subtype knock-out mice compared with their wild-type controls. The results are expressed as mean Ϯ SEM DCX-positive cells per section (n ϭ 5-6/group).
positive cells acquired a neuronal phenotype with far fewer numbers taking on a glial fate. BrdU-positive cells that did not colocalize with either NeuN or GFAP may represent as yet undifferentiated progenitors. We also examined whether ␣ 2 -adrenoceptor stimulation would influence earlier stages of maturation of hippocampal progenitors by addressing the percentage colocalization of BrdU with DCX. Using a BrdU labeling paradigm (supplemental Fig. 2 , available at www.jneurosci.org as supplemental material) that did not involve a washout following BrdU administration to drug-naive animals, we carried out a short-duration (7 d) treatment with the ␣ 2 -adrenoceptor agonist, guanabenz. BrdU-DCX percentage colocalization was unaltered following guanabenz treatment (supplemental Fig. 2 , available at www.jneurosci.org as supplemental material).
␣ 2 -Adrenoceptor blockade accelerates antidepressant-induced adult hippocampal neurogenesis To assess whether ␣ 2 -adrenoceptor blockade accelerates the effects of antidepressant drugs on adult hippocampal progenitor proliferation, we examined the influence of combined treatment (7 or 21 d) with the ␣ 2 -adrenoceptor antagonist yohimbine and the tricyclic antidepressant imipramine on BrdU-positive cell number in the SGZ/GCL (Fig. 5A) . At 21 d, a time-point when antidepressant treatments have been previously reported to enhance BrdU-positive cell number (Malberg et al., 2000 , Santarelli et al., 2003 , we observed a significant increase in the number of BrdU-positive cells in both the group that received only imipramine (Fig. 5 F, G) and the group that received combined yohimbine and imipramine treatment (Fig. 5 F, G) . Two-way ANOVA analysis of the 21 d treatment experiment indicated no significant interaction of yohimbine ϫ imipramine (F (1,12) ϭ 1.22, p ϭ 0.29). In contrast, only the combined yohimbine-and imipramine-treated group showed a significant increase in the number of BrdUpositive cells in the SGZ at the 7 d time point (Fig. 5 B, C) . Two-way ANOVA revealed a significant yohimbine ϫ imipramine interaction in the 7 d treatment experiment (F (1,20) ϭ 20.99, p ϭ 0.0002). Imipramine treatment by itself for 7 d showed no significant effect on hippocampal progenitor proliferation (Fig. 5C ). These results indicate that coadministration of yohimbine with imipramine shortens the duration of antidepressant treatment required to increase adult hippocampal progenitor proliferation.
We also examined the effects of the above combined treatments for 7 or 21 d on the number of DCX-positive immature neurons in the SGZ/GCL. At 21 d, both the imipramine and combined yohimbine and imipramine treatment groups showed a significant increase in the number of DCX-positive cells/section (Fig. 5 H, I ). Two-way ANOVA revealed no significant yohimbine ϫ imipramine interaction at 21 d (F (1,20) ϭ 0.69, p ϭ 0.42). At 7 d, we did not observe a change in DCX-positive cell numbers in any of the groups (Fig. 5 D, E) . Although a change in DCXpositive cell number was not seen at 7 d after combined treatment, 14 d of yohimbine and imipramine coadministration resulted in a significant increase in DCX-positive cell number (14 day combined yohimbine ϩ imipramine experiment, number of DCX-positive cells/section: control ϭ 153.60 Ϯ 16.02, yohimbine ϭ 154.43 Ϯ 11.57, imipramine ϭ 154.60 Ϯ 10.63, yohimbine ϩ imipramine ϭ 225.20 Ϯ 14.96). Two-way ANOVA analysis indicated a significant yohimbine ϫ imipramine inter- We next assessed whether short-duration (7 d) combined yohimbine and imipramine treatment influenced the morphological maturation of DCX-positive immature neurons. DCXpositive neurons were subdivided into (1) those without tertiary dendrites (Fig. 6 A) , and (2) those bearing tertiary dendrites (Fig.  6 B) , as described previously (Wang et al., 2008) . Combined treatment with yohimbine and imipramine for 7 d significantly enhanced the number of DCX-positive cells bearing complex, tertiary dendrites (Fig. 6C) . Individual yohimbine or imipramine treatment had no significant effect on the morphology of DCXpositive cells (Fig. 6C) . Two-way ANOVA indicated a significant yohimbine ϫ imipramine interaction (F (1,15) ϭ 7.52, p ϭ 0.0151). This effect was seen although no changes in DCXpositive cell number were observed with 7 d combined treatment (Fig. 5 D, E) , suggesting a shift in distribution of DCX-positive cells to those bearing a more complex morphology. Previous studies indicate that chronic (28 d), but not subchronic (5 d), antidepressant treatment enhances the dendritic maturation of immature newborn neurons (Wang et al., 2008) . Our results indicate that combined yohimbine and imipramine administration shifts the effects of antidepressant treatment on morphological maturation to an earlier onset.
We then addressed whether the expression of NeuroD, a neurogenic transcription factor required for the survival and maturation of hippocampal progenitors (Gao et al., 2009) , is altered in the SGZ following short-duration yohimbine and imipramine treatment. The combined yohimbine-and imipramine-treated group showed a significant increase in the number of NeuroDpositive cells/section in the SGZ at the 7 d time point (Fig. 6 D, E) . Two-way ANOVA revealed a significant yohimbine ϫ imipramine interaction (F (1,15) ϭ 20.25, p ϭ 0.0004). Imipramine treatment by itself showed no significant effect on NeuroD-positive cell number (Fig. 6 E) . A previous study indicates that chronic (14 d), but not subchronic (5 d), antidepressant treatment enhances NeuroD-positive cell number in the SGZ/GCL (Larsen et al., 2007) . Our results demonstrate that adjunct ␣ 2 -adrenoceptor blockade accelerates the effects of imipramine on NeuroDpositive progenitor number, and thus indicates that the increased numbers of hippocampal progenitors observed following combined treatment exhibit neuronal commitment.
To address whether short-duration yohimbine and imipramine treatment influences the developmental progression of newborn neurons we examined the percentage colocalization of BrdU-positive cells with calretinin, a transient marker of immature neurons (Brandt et al., 2003) . Drug-naive animals were subjected to a BrdU labeling paradigm (supplemental Fig. 3 , available at www.jneurosci.org as supplemental material), following which they received 7 d combined yohimbine and imipramine treatment. Confocal analysis indicated a significant increase in the percentage BrdU/calretinin colocalization in the combined yohimbine and imipramine treatment group, with no BrdU/calretinin colocalization observed in vehicle, yohimbine or imipramine treatment groups at this time point (supplemental Fig. 3 , available at www.jneurosci.org as supplemental material). Two-way ANOVA indicated a significant yohimbine ϫ imipramine interaction (F (1,16) ϭ 6.77, p ϭ 0.0019). Together, the influence of combined yohimbine and imipramine treatment on DCX morphology, NeuroD-positive cell number and BrdU/calretinin colocalization suggest that combination treatment influences the differentiation of newborn neurons within the adult hippocampal neurogenic niche.
To confirm whether the increase in BrdU-positive cell number that is observed with short-duration (7 d) combined yohimbine and imipramine treatment results in eventual differentiation into neurons or glia, we carried out triple immunolabeling with BrdU, NeuN and GFAP. Confocal analysis revealed that most of the BrdU-positive cells 4 weeks later had differentiated into neurons with few taking on a glial phenotype. The percentage distribution of BrdU cells that acquire a neuronal or glial fate was not altered across all the treatment groups at this time point (Fig. 7 A, B) .
Short-duration combined yohimbine and imipramine treatment enhances hippocampal gene expression of BDNF, VEGF, FGF-2, VGF, and Arc
As the next step we addressed whether short-duration (7 d) combined yohimbine and imipramine treatment is sufficient to increase the hippocampal expression of trophic factors like BDNF, VEGF, and FGF-2 that are known to be enhanced only following longer duration (2-3 weeks) antidepressant treatment (Nibuya et al., 1995 , Dias et al., 2003 Warner-Schmidt and Duman, 2007; Bachis et al., 2008) . We also examined the influence of this treatment on the gene expression of the neuropeptide VGF, the immediate early gene Arc and the transcription factor CREB, which are regulated by chronic antidepressant treatment and contribute to antidepressant efficacy (Nibuya et al., 1996; Pei et al., 2003; Thakker-Varia et al., 2007; Molteni et al., 2008) . We found that combined yohimbine and imipramine administration for 7 d resulted in a robust and significant increase (176%) in BDNF mRNA in the dentate gyrus (DG) (Fig. 8 A, B) . Treatment with only yohimbine or imipramine for 7 d did not alter BDNF mRNA expression in the DG. Two-way ANOVA indicated a significant yohimbine ϫ imipramine interaction (F (1,16) ϭ 880.36, p Ͻ 0.0001). Seven day combination treatment also significantly induced the mRNA expression of VEGF (79%) (Fig. 8C,D) and FGF-2 (77%) (Fig. 8 E, F ) in the DG. Yohimbine or imipramine treatments by themselves for 7 d did not alter VEGF or FGF-2 mRNA expression in the DG significantly. However, the two-way ANOVA analysis of the VEGF and FGF-2 data indicated no significant yohimbine ϫ imipramine interaction (VEGF: F (1,13) ϭ 0.66, p ϭ 0.43; FGF-2: F (1,12) ϭ 2.09, p ϭ 0.17). Furthermore, the short-duration (7 d) combined treatment of yohimbine and imipramine significantly upregulated (30%) the mRNA expression of the neuropeptide VGF in the DG (Fig.  8G,H ) . Seven day of treatment with imipramine alone was also sufficient to induce a significant increase (19%) in VGF expression. Two-way ANOVA analysis of a yohimbine ϫ imipramine interaction indicated a trend toward significance (F (1,12) ϭ 3.89, p ϭ 0.0721). Interestingly, 7 d combined yohimbine and imipramine treatment also resulted in a highly robust increase (ϳ5-fold) in the mRNA expression of the immediate early gene Arc within the DG (Fig. 8 I, J ) . No change in Arc mRNA levels was observed with individual yohimbine or imipramine treatment for 7 d. Two-way ANOVA revealed a significant yohimbine ϫ imipramine interaction (F (1,16) ϭ 6894.33, p Ͻ 0.0001). In contrast to the effects seen with trophic factors, the neuropeptide VGF and the immediate early gene Arc, combined yohimbine and imipramine treatment did not alter CREB mRNA expression in the DG (Fig. 8 K, L) .
To address whether short-duration (7 d) combined yohimbine and imipramine treatment changes hippocampal norepinephrine levels we carried out HPLC analysis. Hippocampal levels of norepinephrine in all treatment groups were found to be indistinguishable from vehicle-treated controls [level of NE (ng/g tissue weight) in the hippocampus: vehicle ϭ 303.57 Ϯ 23.35, yohimbine ϭ 256.76 Ϯ 10.99, imipramine ϭ 254.22 Ϯ 13.68, yohimbine ϩ imipramine ϭ 257.30 Ϯ 16.54].
␣ 2 -Adrenoceptor blockade accelerates the behavioral effects of the antidepressant imipramine in the novelty suppressed feeding test Given the effects of short-duration (7 d) combined yohimbine and imipramine treatment on hippocampal neurogenesis and Figure 8 . Short-duration combined yohimbine and imipramine treatment for 7 d upregulates the mRNA expression of plasticity associated genes like BDNF, VEGF, FGF-2, VGF, and Arc in the dentate gyrus. Rats received treatment with the ␣ 2 -adrenoceptor antagonist, yohimbine and the antidepressant, imipramine for 7 d before kill and processing for in situ hybridization as described in Materials and Methods. In situ hybridization for BDNF, VEGF, FGF-2, VGF, Arc, and CREB transcripts was performed using specific riboprobes and transcript levels in the hippocampal DG subfield were quantified using densitometric analysis. gene expression of plasticity associated genes, we asked whether this short-duration combined treatment is also capable of inducing a behavioral response in the NSF test (Fig. 9A ) that has been previously shown to be responsive to chronic (2-3 weeks), but not acute, antidepressant administration (Bodnoff et al., 1988; Santarelli et al., 2003) . Following 21 d of treatment, we observed a significant reduction in the latency to feed in both the group that received just the antidepressant, imipramine, as well as the group that received the combination treatment with yohimbine and imipramine, with no significant effect of only yohimbine treatment (Fig. 9C) . In contrast, we observed a significant reduction in the latency to feed only in the group that received a combination treatment with both yohimbine and imipramine in the short (7 d) duration experiment (Fig. 9B) . Two-way ANOVA analysis of the 7 d experiment revealed a significant yohimbine ϫ imipramine interaction (F (1,36) ϭ 4.93, p ϭ 0.0328). To control for effects of drug treatments on appetite, we also assessed home cage food consumption immediately following the NSF test. Food consumption in the home-cage was found to be unaltered across all the treatment groups [home cage food consumption-7 d experiment (g/30 min): vehicle ϭ 5.14 Ϯ 0.34, yohimbine ϭ 5.28 Ϯ 0.25, imipramine ϭ 4.43 Ϯ 0.62, yohimbine ϩ imipramine ϭ 4.54 Ϯ 0.80]. Together, these results suggest that a short-duration (7 d) combination treatment with yohimbine and imipramine reduces the time lag to observe a behavioral response in the NSF test.
Discussion
The novel findings of our study are that ␣ 2 -adrenoceptor stimulation decreases adult hippocampal neurogenesis, while simultaneous ␣ 2 -adrenoceptor blockade and antidepressant treatment hastens effects on hippocampal neurogenesis, plasticity-associated gene expression, and depression-related behavior. Our results highlight the importance of ␣ 2 -adrenoceptors as targets for rapid-action antidepressants.
Adult hippocampal neurogenesis encompasses progenitor proliferation, survival, and differentiation resulting in newborn neuron integration into hippocampal circuitry (Ming and Song, 2005) . The hippocampal neurogenic niche receives dense noradrenergic innervation, expresses all the different classes of adrenoceptors, and hippocampal progenitor proliferation is stimulated by norepinephrine (Nicholas et al., 1996; Kulkarni et al., 2002) (D. Jhaveri and P. Bartlett, personal communication) . Paradoxically, we found that ␣ 2 -adrenoceptor stimulation in vivo decreases hippocampal progenitor proliferation. ␣ 2 -Adrenoceptors exist both as heteroceptors on target neurons receiving noradrenergic innervation, and as ␣ 2 -autoreceptors that decrease norepinephrine release. Our in vitro and in vivo findings support a role for ␣ 2 -heteroceptors in mediating the effects on adult hippocampal progenitor turnover. First, we provide evidence that dispersed adult hippocampal progenitors in culture express the ␣ 2 -adrenoceptor subtypes, and exhibit decreased BrdU-incorporation following ␣ 2 -adrenoceptor stimulation. Second, ␣ 2 -adrenoceptor agonists significantly reduce neurosphere frequency in the neurosphere assay indicating a direct effect on the turnover of adult neural stem cells. Finally, our in vivo finding that this decreased proliferation persists in Dbh Ϫ/Ϫ mice indicates an effect on hippocampal progenitor proliferation via ␣ 2 -heteroceptors. While ␣ 2 -adrenoceptor stimulation selectively influences the proliferation, but not the survival or differentiation of hippocampal progenitors, ␣ 2 -adrenoceptor blockade does not influence hippocampal neurogenesis. Our results differ from a previous study (Rizk et al., 2006 ) that reported enhanced progenitor survival following long duration treatment with the ␣ 2 -adrenoceptor antagonist dexefaroxan. This discrepancy may be a consequence of differences in drug choice, dose, route of administration or treatment duration. We also did not observe any change in progenitor proliferation or immature neuron number in ␣ 2A -, ␣ 2C -, and ␣ 2AC -adrenoceptor knock-out mice. Together, our results indicate that ␣ 2 -adrenoceptors exert a stimulation-induced, but not a basal tonic, inhibitory effect on adult hippocampal progenitor turnover.
Interestingly, ␣ 2 -adrenoceptors are expressed within proliferative germinal zones, and their stimulation decreases DNA synthesis in the developing forebrain (Lidow and Rakic, 1994; Kreider et al., 2004) suggesting possible common mechanisms in the developing and adult brain. Given that cAMP-CREB signaling enhances adult hippocampal neurogenesis , ␣ 2 -adrenoceptor activation may decrease progenitor turnover through a G i -mediated inhibition of adenylate cyclase. The mechanistic underpinnings of the effects of ␣ 2 -adrenoceptors on adult hippocampal progenitors warrant further investigation.
Hippocampal volumetric loss is observed in recurrent major depression, and decreased neurogenesis reported in animal models of depression (Campbell et al., 2004; Sahay and Hen, 2007) . Enhanced ␣ 2 -adrenoceptor density and mRNA expression within limbic brain regions is observed in animal models of depression (Ribas et al., 2001; Flügge et al., 2003) . Furthermore, increased hippocampal ␣ 2 -adrenoceptor binding (Meana et al., Figure 9 . ␣ 2 -Adrenoceptor blockade hastens the effects of the antidepressant imipramine on behavior in the NSF test. Rats received combined treatment with the ␣ 2 -adrenoceptor antagonist, yohimbine and the antidepressant imipramine for 7 or 21 d, and behavior was assessed using the NSF test as described in Materials and Methods. Antidepressants require chronic (2-3 weeks) administration to exhibit behavioral effects on the NSF test. A, Shown is a schematic illustration of the side, and top, views of an NSF arena in which food pellets are placed in the center on an illuminated platform and latency to feed is measured. C, Administration of imipramine or combined yohimbine ϩ imipramine treatment for 21 d resulted a significant reduction in the latency to feed in the NSF test. Twenty-one day yohimbine treatment did not result in a significant effect on the NSF test. B, A reduced latency to feed was observed in the short-duration (7 d) experiment only in the combined yohimbine ϩ imipramine treatment group. The results are expressed as the mean Ϯ SEM latency to feed in seconds (n ϭ 10/group). *p Ͻ 0.05 compared with vehicle, # p Ͻ 0.05 compared with yohimbine, $ p Ͻ 0.05 compared with imipramine (ANOVA and Bonferroni post hoc test).
1992; González et al., 1994) and prefrontal ␣ 2A -adrenoceptor immunoreactivity (García-Sevilla et al., 1999) have been observed in postmortem studies of major depression. While it remains uncertain whether the changes in ␣ 2 -adrenoceptor binding reflect alterations in terminal ␣ 2 -autoreceptors or ␣ 2 -heteroceptors in target fields, the mRNA expression changes indicate enhanced expression of ␣ 2 -heteroceptors in limbic neurocircuitry following chronic stress. Our results suggest a possible role for ␣ 2 -heteroceptors in the neurogenic decline observed in animal models of depression.
The "neurotrophic" and "neurogenic" hypotheses of depression posit a role for decreased trophic support and neurogenesis in the hippocampal damage observed in depression, and a contribution of antidepressant-induced trophic factor expression and hippocampal neurogenesis to their therapeutic action (Sahay and Hen, 2007; Schmidt and Duman, 2007) . It is noteworthy that the neurotrophic and neurogenic changes exhibit a slow onset, and parallel the time course required for the behavioral benefits of sustained antidepressant administration (Sahay and Hen, 2007; Schmidt and Duman, 2007) . One of our most interesting and novel findings is that ␣ 2 -adrenoceptor blockade accelerates the effects of chronic antidepressant treatment on hippocampal neurogenesis and trophic factor gene expression associated with faster behavioral effects (Fig. 10) .
Combined 7 d yohimbine and imipramine (YϩI) treatment significantly improved behavioral outcome in the NSF test, which is normally sensitive only to longer periods (3 weeks) of antidepressant treatment (Santarelli et al., 2003) . YϩI treatment also increased hippocampal progenitor proliferation and NeuroDpositive neuroblast number within 7 d, an effect not observed with imipramine treatment alone. Furthermore, a striking shift in the distribution of DCX-positive cells to those bearing complex, tertiary dendritic morphology was observed in the 7 d YϩI group. Enhanced BrdU/calretinin percentage colocalization observed at 7 d in the YϩI group suggests an influence on the developmental progression of immature neurons. Together, our results indicate that simultaneous ␣ 2 -adrenoceptor blockade hastens effects of antidepressant treatment on distinct aspects of adult hippocampal neurogenesis.
It is unlikely that increased progenitor proliferation contributes to the behavioral effects observed with 7 d YϩI treatment; rather our observation of effects on the morphological complexity of DCX-positive cells suggest that the integration of immature neurons into hippocampal neurocircuitry may be accelerated. It is tempting to speculate that this component of the neurogenic effects of 7 d YϩI treatment may contribute to the rapid rate of behavioral response. Future experiments are required to address whether 7 d YϩI treatment accelerates the differentiation, integration and recruitment of newborn neurons into hippocampal circuitry. Interestingly, 21 d YϩI treatment increased progenitor proliferation and DCX-positive cell number to a similar extent as imipramine treatment alone, suggesting that combined treatment may largely involve acceleration, rather than augmentation, of the neurogenic effects of imipramine.
Seven day YϩI treatment increased BDNF, VEGF, and FGF-2 mRNA expression in the DG subfield, an effect not observed with imipramine treatment. The combined treatment also enhanced VGF expression, an effect also observed with imipramine treatment. The effects of YϩI do not appear simply additive, and suggest the possible recruitment of distinct signaling mechanisms. The robust increase in the expression of the activitydependent gene Arc (Bramham et al., 2008) in the DG subfield indicates enhanced neuronal activity following YϩI treatment. It is interesting to note that enhanced DG activity as measured by voltage-sensitive dye imaging has been previously strongly linked to antidepressant-induced neurogenic and behavioral responses (Airan et al., 2007) . Neuronal activity is known to recruit latent stem/progenitor cells in the adult hippocampus, and enhance trophic factor expression (Gall and Lauterborn, 1992; Walker et al., 2008) . Trophic factors could serve to link neuronal activity to structural plasticity in the hippocampal neurogenic niche. Our results also raise the strong possibility that non-cell autonomous effects via enhanced neuronal activity and trophic factor release may also contribute to the neurogenic effects of YϩI treatment. Furthermore, BDNF, FGF-2, VEGF, and VGF are implicated as key mediators of both the neurogenic and behavioral effects of antidepressants (Palmer et al., 1999; Warner-Schmidt et al., 2007; Bachis et al., 2008; Li et al., 2008; Thakker-Varia et al., 2007; Perez et al., 2009) , and may play a critical role in mediating faster effects on neurogenesis and behavior with 7 d YϩI treatment.
Previous clinical literature has suggested the coadministration of ␣ 2 -adrenoceptor antagonists with antidepressants as a therapeutic strategy to hasten antidepressant responses (Blier, 2003) . The mode of action for these faster effects has been unclear. Our results suggest that adjunct ␣ 2 -adrenoceptor antagonists accelerate the effects of antidepressant treatment on the slow-onset adaptive changes in neurogenesis and trophic factor expression that are thought to underlie the behavioral effects of antidepressants. Our findings support the view that structural remodeling and enhanced trophic support may be key events determining the latency in onset of antidepressant action. At present, we cannot distinguish whether blockade of ␣ 2 -autoreceptors or heteroceptors, or a combination of both, contribute to the faster effects of Figure 10 . Short-duration (7 d) combined treatment with the ␣ 2 -adrenoceptor antagonist, yohimbine and the antidepressant, imipramine treatment hastens the effects of antidepressant treatment on adult hippocampal progenitor proliferation, morphological maturation of newborn neurons and the expression of plasticity-associated genes. A, Shown in the illustration are the effects of combined yohimbine and imipramine treatment on adult hippocampal neurogenesis. The short-duration combined treatment results in an increased proliferation of adult hippocampal progenitors, whereas treatment with the antidepressant imipramine alone does not alter hippocampal progenitor proliferation. While the combination treatment for 7 d does not increase DCX-positive cell number, it significantly shifts the ratio of DCX-positive cells toward those bearing a more complex dendritic morphology indicating an effect of yohimbine ϩ imipramine treatment on the morphological maturation of immature neurons. B, Shown in the illustration are the effects of combined yohimbine and imipramine treatment on the mRNA expression of trophic factors like BDNF, VEGF, and FGF-2 and plasticity-associated transcripts like Arc, VGF, and CREB. The combination treatment significantly enhances the expression of BDNF, VEGF, FGF-2, VGF and Arc in the DG subfield of the hippocampus. Effects on mRNA expression levels are schematized based on the color scale (not to exact scale).
YϩI treatment. It has been suggested that concomitant blockade of inhibitory presynaptic ␣ 2 -autoreceptors would increase noradrenergic neurotransmission, whereas in the absence of such a blockade a desensitization/downregulation of presynaptic ␣ 2 -adrenoceptors would have to precede an increase in noradrenergic neurotransmission, thus contributing to the delay in antidepressant action (Blier, 2003) . It is possible that we observed faster effects with YϩI treatment due to the blockade of inhibitory ␣ 2 -autoreceptors, or heteroceptors on serotonergic neurons, thus enhancing noradrenergic and serotonergic neurotransmission. Our failure to observe a change in hippocampal norepinephrine levels following 7 d YϩI treatment does not rule out possible autoreceptor effects, particularly since we measured tissue norepinephrine levels, which are not always correlated with extracellular norepinephrine that is available for signaling. Future studies using genetic perturbation approaches will be required to dissect out the contribution of ␣ 2 -autoreceptors and heteroceptors to the faster effects of adjunct ␣ 2 -adrenoceptor antagonist and antidepressant treatment.
In conclusion, we demonstrate that ␣ 2 -adrenoceptor stimulation decreases adult hippocampal neurogenesis, while concomitant ␣ 2 -adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment. The delayed onset of action of antidepressants is a major drawback for both treatment and compliance. Our results highlight the importance of ␣ 2 -adrenoceptors in modulating the speed of antidepressant response, and motivate future research in the development of rapid-action antidepressants that target the ␣ 2 -adrenoceptor.
